Clinical trial EMR 200066-007
A multicentre, open label, randomized Phase II trial of the MEK inhibitor pimasertib or dacarbazine in previously untreated subjects with NRas mutated locally advanced or metastatic malignant cutaneous melanoma
| Cancers | |
|---|---|
| Organ | Skin |
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 2 |
| Academic trial | Non |
| Sponsor | Merck Serono |
| EudraCT Identifier | 2012-002669-37 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT01693068 |
| Inclusion criteria | N-Ras mutated |
| Last update |